Table 1.
Patient characteristics
| Control (n = 134) | COVID-19 (n = 76) | P-value | |
|---|---|---|---|
| Age (years) | 81.9 ± 6.4 | 80.9 ± 6.9 | 0.296 |
| Female | 79 (59) | 33 (43.4) | 0.03 |
| Body Mass Index (kg/m2) | 27.9 ± 5.9 | 28.1 ± 4.6 | 0.389 |
| Diabetes Mellitus | 37 (27.6) | 17 (22.4) | 0.404 |
| Creatinine (mmol/l) | 106.2 ± 75.2 | 104.9 ± 85.9 | 0.390 |
| Previous MI | 14 (10.4) | 11 (14.5) | 0.387 |
| Previous Cardiac Surgery | 11 (8.2) | 13 (17.1) | 0.051 |
| Prior balloon-aortic valvuloplasty (BAV) | 4 (3) | 1 (1.3) | 0.446 |
| Coronary artery disease in >1 artery∗ | 9 (6.7) | 7 (9.2) | 0.513 |
| Chronic pulmonary disease | 49 (36.6) | 28 (36.8) | 0.968 |
| Severe liver disease | 5 (3.7) | 1 (1.3) | 0.313 |
| Previous cerebrovascular disease | 32 (23.8) | 10 (13.2) | 0.062 |
| Extracardiac arteriopathy | 13 (9.7) | 9 (11.8) | 0.626 |
| Atrial fibrillation | 56 (41.8) | 19 (25) | 0.015 |
| Katz Index | 5.4 ± 0.9 | 5.7 ± 0.5 | 0.228 |
| Left Ventricular Ejection Fraction (%) | |||
| >50 | 92 (68.7) | 51 (67.1) | 0.817 |
| 36-49 | 26 (19.4) | 15 (19.7) | 0.953 |
| <35 | 16 (11.9) | 10 (13.2) | 0.797 |
| EuroSCORE II(%) | 4.51 ± 7.1 | 4.6 ± 4.4 | 0.344 |
| Primary Aortic Valve Pathology | |||
| Aortic Stenosis | 130 (97) | 73 (96) | 0.709 |
| Mixed aortic valve disease | 4 (3) | 3 (3.9) | 0.709 |
| Mean aortic valve gradient (mmHg) | 49.3 ± 15.5 | 45.1 ± 15.4 | 0.133 |
| Aortic valve area (cm2) | 0.8 ± 0.6 | 0.9 ± 0.8 | 0.007 |
| Extensive calcification of ascending aorta | 9 (6.7) | 4 (5.3) | 0.675 |
| Symptoms | |||
| CCS angina III or IV | 1 (0.7) | 2 (2.6) | 0.269 |
| NYHA class III or IV | 120 (89.5) | 64 (84.2) | 0.259 |
Values are mean ± SD or N (%).
EuroSCORE = European System for Cardiac Operative Risk Evaluation; MSCT = multislice computed tomographic; CCS = Canadian Cardiovascular Society; NYHA = New York Heart Association.
∗
Coronary artery disease defined as >70% stenosis.